175 related articles for article (PubMed ID: 20832093)
21. Towards nationwide control of schistosomiasis in Yemen: a pilot project to expand treatment to the whole community.
Oshish A; AlKohlani A; Hamed A; Kamel N; AlSoofi A; Farouk H; Ben-Ismail R; Gabrielli AF; Fenwick A; French MD
Trans R Soc Trop Med Hyg; 2011 Nov; 105(11):617-27. PubMed ID: 21907376
[TBL] [Abstract][Full Text] [Related]
22. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.
Doenhoff MJ; Hagan P; Cioli D; Southgate V; Pica-Mattoccia L; Botros S; Coles G; Tchuem Tchuenté LA; Mbaye A; Engels D
Parasitology; 2009 Nov; 136(13):1825-35. PubMed ID: 19281637
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of praziquantel in treating natural schistosome infections in common mergansers.
Blankespoor CL; Reimink RL; Blankespoort HD
J Parasitol; 2001 Apr; 87(2):424-6. PubMed ID: 11318576
[TBL] [Abstract][Full Text] [Related]
24. The presumptive treatment of all school-aged children is the least costly strategy for schistosomiasis control in Plateau and Nasarawa states, Nigeria.
Gutman J; Richards FO; Eigege A; Umaru J; Alphonsus K; Miri ES
Ann Trop Med Parasitol; 2009 Sep; 103(6):501-11. PubMed ID: 19695155
[TBL] [Abstract][Full Text] [Related]
25. Schistosomiasis in African infants and preschool children: let them now be treated!
Stothard JR; Sousa-Figueiredo JC; Betson M; Bustinduy A; Reinhard-Rupp J
Trends Parasitol; 2013 Apr; 29(4):197-205. PubMed ID: 23465781
[TBL] [Abstract][Full Text] [Related]
26. Control of schistosomiasis in sub-Saharan Africa: progress made, new opportunities and remaining challenges.
Stothard JR; Chitsulo L; Kristensen TK; Utzinger J
Parasitology; 2009 Nov; 136(13):1665-75. PubMed ID: 19814845
[TBL] [Abstract][Full Text] [Related]
27. Putting the treatment of paediatric schistosomiasis into context.
Mduluza T; Mutapi F
Infect Dis Poverty; 2017 Apr; 6(1):85. PubMed ID: 28388940
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a 'tablet pole' for the administration of praziquantel in sub-Saharan Africa.
Montresor A; Engels D; Chitsulo L; Bundy DA; Brooker S; Savioli L
Trans R Soc Trop Med Hyg; 2001; 95(5):542-4. PubMed ID: 11706670
[TBL] [Abstract][Full Text] [Related]
29. Decades down the line: the viability of praziquantel for future schistosomiasis treatment.
Cioli D; Basso A; Valle C; Pica-Mattoccia L
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):835-7. PubMed ID: 23030319
[No Abstract] [Full Text] [Related]
30. Human schistosomiasis in the post mass drug administration era.
Mutapi F; Maizels R; Fenwick A; Woolhouse M
Lancet Infect Dis; 2017 Feb; 17(2):e42-e48. PubMed ID: 27988094
[TBL] [Abstract][Full Text] [Related]
31. Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis.
Stothard JR; Sousa-Figueiredo JC; Navaratnam AM
Expert Rev Anti Infect Ther; 2013 Jul; 11(7):733-52. PubMed ID: 23879611
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of different approaches to mass delivery of praziquantel among school-aged children in rural communities in Nigeria.
Mafe MA; Appelt B; Adewale B; Idowu ET; Akinwale OP; Adeneye AK; Manafa OU; Sulyman MA; Akande OD; Omotola BD
Acta Trop; 2005 Feb; 93(2):181-90. PubMed ID: 15652332
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of efficacy of school-based anthelmintic treatments against anaemia in children in the United Republic of Tanzania.
Guyatt HL; Brooker S; Kihamia CM; Hall A; Bundy DA
Bull World Health Organ; 2001; 79(8):695-703. PubMed ID: 11545325
[TBL] [Abstract][Full Text] [Related]
34. Schistosomiasis: challenges for control, treatment and drug resistance.
Fenwick A; Webster JP
Curr Opin Infect Dis; 2006 Dec; 19(6):577-82. PubMed ID: 17075334
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the efficacy and safety of praziquantel administered in single dose of 40 versus 60 mg/kg for treating urinary schistosomiasis in Mauritania].
Ouldabdallahi M; Ousmane B; Ouldbezeid M; Mamadou D; Konaté L; Chitsulo L
Bull Soc Pathol Exot; 2013 Aug; 106(3):167-9. PubMed ID: 23681759
[TBL] [Abstract][Full Text] [Related]
36. [Progress of research on preparation and application of praziquantel].
Wu DZ; Ma Z; Liu YF; Zhu WF; Ning A
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2013 Apr; 25(2):194-6. PubMed ID: 23894845
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of praziquantel during the incubation and invasive phase of Schistosoma haematobium schistosomiasis in 18 travelers.
Grandière-Pérez L; Ansart S; Paris L; Faussart A; Jaureguiberry S; Grivois JP; Klement E; Bricaire F; Danis M; Caumes E
Am J Trop Med Hyg; 2006 May; 74(5):814-8. PubMed ID: 16687686
[TBL] [Abstract][Full Text] [Related]
38. The cost of large-scale school health programmes which deliver anthelmintics to children in Ghana and Tanzania. The Partnership for Child Development.
Acta Trop; 1999 Jul; 73(2):183-204. PubMed ID: 10465058
[TBL] [Abstract][Full Text] [Related]
39. Interactions between Schistosoma haematobium and human immunodeficiency virus type 1: the effects of coinfection on treatment outcomes in rural Zambia.
Mwanakasale V; Vounatsou P; Sukwa TY; Ziba M; Ernest A; Tanner M
Am J Trop Med Hyg; 2003 Oct; 69(4):420-8. PubMed ID: 14640503
[TBL] [Abstract][Full Text] [Related]
40. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.
Doenhoff MJ; Pica-Mattoccia L
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):199-210. PubMed ID: 16597202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
